Developer docs
API playgroundTry for free, no card

Search company profiles

Meribel Pharma Solutions

Full company profile

uuid00eqynh

Namestring
Meribel Pharma Solutions
Legal namestring
BW CDMO Topco Uk Limited
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Meribel Pharma Solutions is a UK-headquartered, mid-size European pharmaceutical Contract Development and Manufacturing Organisation (CDMO) that was formed in 2024 through the merger of Synerlab Group and seven manufacturing sites formerly operated by Recipharm, and officially launched commercial operations in April 2025. The company operates an integrated network of 13 manufacturing facilities — six in France, two in Spain, and five in Sweden — with more than 2,000 full-time employees across five countries, and is backed by Blue Wolf Capital Partners, a US middle-market private equity firm focused on industrial and healthcare sectors.

The company offers end-to-end CDMO services spanning formulation development, analytical development, process development, commercial-scale manufacturing, packaging, regulatory affairs, technology transfer, and specials (unlicensed medicines). It manufactures across five principal dosage forms — oral solids, liquids, semi-solids, steriles, and sachets/stick packs — with particular domain specialisation in sterile multidoses (drawing on over three decades of legacy expertise), lyophilisation (including cryogenic and API lyophilisation), and sachets/stick packs. Multiple sites hold cGMP (EU), FDA, and PMDA (Japan) certifications, along with ISO 13485, 14001, and 45001 credentials at Swedish sites, enabling the company to serve pharmaceutical clients across major regulated markets.

Meribel operates a B2B contract-services revenue model, generating revenue through long-term commercial supply and development contracts with pharmaceutical companies — including generic drug manufacturers, innovative pharma, and biotechs — at negotiated per-project pricing. The go-to-market is enterprise sales-led, supported by a Chief Commercial Officer, dedicated commercial teams, and active presence at industry events such as CPHI Frankfurt (October 2025) and CDMO Live Rotterdam (May 2026, Gold Partner). The company has stated an ambition to double revenue within five years under Blue Wolf Capital's ownership.

Short descriptiontext

Meribel Pharma Solutions is a UK-headquartered mid-size European CDMO operating 13 manufacturing sites across France, Spain, and Sweden with 2,000+ staff, offering end-to-end pharmaceutical development, manufacturing, and packaging services — with specialisations in sterile multidoses, lyophilisation, and sachets/stick packs — to pharmaceutical and biotech clients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices13 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract pharmaceutical manufacturing, lyophilisation services, sterile manufacturing, oral solid dose, pharmaceutical development services
Industry5 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Contract Manufacturing (CDMO)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Development and Manufacturing Services
TypeProfessional Services
Description

As a CDMO, Meribel Pharma Solutions generates revenue through providing end-to-end pharmaceutical development and manufacturing services to pharmaceutical companies. Services include formulation development, analytical development, process development, manufacturing, packaging, regulatory affairs, and technology transfer. Revenue is generated through long-term contracts with pharmaceutical companies for product development and commercial manufacturing.

meribelpharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Meribel Pharma Solutions is a mid-size European Contract Development and Manufacturing Organisation (CDMO) providing end-to-end pharmaceutical services from concept through commercialisation. The company delivers formulation development, analytical development, process development, manufacturing, packaging, regulatory affairs, and technology transfer across 13 manufacturing sites in France, Spain, and Sweden. Core specialisations include lyophilisation (including API and cryogenic), sterile multidose manufacturing with terminal sterilisation, sachets and stick packs, oral solid dose production, semi-solids, and sterile non-injectable liquids for pharmaceutical company clients.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Meribel Pharma Solutions is a mid-size, full-service Contract Development and Manufacturing Organisation (CDMO) offering an integrated network of pharmaceutical development and manufacturing services across Europe. The company's product portfolio includes three core service areas: Development Services (comprising Formulation Development, Analytical Development, and Process Development), Manufacturing Services for multiple dosage forms, and Regulatory Affairs. The company specialises in five key dosage forms: Oral Solids, Liquids, Semi-Solids, Steriles, and Sachets/Stick Packs. The service offering is built around particular specialisations in sterile multidoses, sterile and non-sterile lyophilised products, API lyophilisation, sachets and stick packs. Additional services include Packaging, Technology Transfer, Specials, and Quality assurance. The integrated network across 13 sites in France, Spain, and Sweden enables seamless support from concept through to commercialisation.

Product and service8 records
1Lyophilisation Services
CategoryCDMO Contract Service
Description

Flexible and responsive lyophilisation (freeze-drying) services across the entire value chain, with particular specialisation in API lyophilisation and cryogenic/extreme cold processing capabilities. Sold to pharmaceutical companies requiring contract lyophilisation manufacturing.

2Sterile Multidose Services
CategoryCDMO Contract Service
Description

Expert sterile multidose development and manufacturing services with over three decades of experience, including sterile and non-sterile lyophilised products, terminal sterilisation, and WFI (Water for Injection) production. Sold to pharmaceutical companies.

3Development Services
CategoryCDMO Contract Service
Description

Comprehensive drug development services including formulation development, analytical development, and process development for pharmaceutical clients. Sold as an integrated development service to pharmaceutical companies.

4Manufacturing Services
CategoryCDMO Contract Service
Description

Diverse manufacturing technologies and experienced team ensuring high-quality and efficient production of drug products across multiple dosage forms. Sold as contract manufacturing to pharmaceutical companies.

5Packaging Services
CategoryCDMO Contract Service
Description

Pharmaceutical packaging solutions grounded in knowledge and insight, including large-scale sachet and stick pack packaging capacity. Sold as contract packaging services to pharmaceutical companies.

6Regulatory Affairs Services
CategoryCDMO Contract Service
Description

Regulatory affairs services in the EU to help navigate the complexities of global pharmaceutical regulations for medicinal products. Sold to pharmaceutical companies requiring multi-jurisdictional regulatory support.

7Technology Transfer Services
CategoryCDMO Contract Service
Description

Flexible approach to technology transfer that adapts to unique customer requirements and timelines, enabling seamless movement of products and processes between sites. Sold to pharmaceutical companies requiring tech transfer support.

8Specials Services
CategoryCDMO Contract Service
Description

Solutions for complex pharmaceutical challenges where standard approaches may not apply. Sold to pharmaceutical companies requiring tailored manufacturing solutions for complex products.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

UK/Northern Ireland-headquartered CDMO with comparable pharmaceutical development, manufacturing, and clinical services. Competes for similar European pharma contracts at greater scale and broader service breadth.

TypeDirect peer
Description

European API and intermediates CDMO spun off from Sanofi in 2022. Comparable regulatory heritage, French-headquartered, and competing for the same European pharma outsourcing customers, particularly on API and complex synthesis.

TypeDirect peer
Description

French-headquartered CDMO specialising in sterile and non-sterile pharmaceutical manufacturing, particularly oral solids and injectables. Directly comparable European mid-size CDMO competing for the same generic and innovative-pharma customers as Meribel.

4Fareva
TypeDirect peer
Description

France-based contract manufacturer with pharmaceutical (CDMO), cosmetic, and industrial operations. Comparable pharmaceutical manufacturing scale and European footprint, especially in France, competing in similar dosage forms.

TypeBroad incumbent
Description

Swiss-headquartered global CDMO leader across small molecules, biologics, and cell/gene therapy. Operates at much larger scale than Meribel but competes for the same European pharma outsourcing wallet, particularly for sterile and complex dosage forms.

TypeDirect peer
Description

Portugal-headquartered CDMO specialising in API development and manufacturing, inhalation, and oral dosage forms. Comparable as a European specialist CDMO serving global pharma with similar regulatory certifications.

7Recipharm
TypeDirect peer
Description

European CDMO focused on small-molecule drug product manufacturing across sterile, semi-solid, and oral solid dosage forms — directly comparable to Meribel across both service offering and target pharma customer base. Seven of Meribel's sites were carved out from Recipharm in 2024.

TypeDirect peer
Description

European CDMO providing API manufacturing (peptides, lipids, carbohydrates) and drug product services across sterile and oral dosage forms. Comparable as a mid-to-large European CDMO platform serving global pharma customers.

TypeDirect peer
Description

European mid-size CDMO with similar portfolio across solid, semi-solid, liquid, and sterile dosage forms. Comparable in scale and footprint, competing head-to-head for mid-size pharma contract manufacturing business.

TypeBroad incumbent
Description

Global large-molecule and small-molecule CDMO with comparable service lines (oral solids, sterile, softgel, biologics). Competes with Meribel for mid-tier pharma contracts but at much greater scale and with broader dosage-form breadth.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries15 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance10 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Meribel Pharma Solutions

Pharmaceutical Contract Manufacturing (CDMO)meribelpharma.com

Meribel Pharma Solutions is a UK-headquartered mid-size European CDMO operating 13 manufacturing sites across France, Spain, and Sweden with 2,000+ staff, offering end-to-end pharmaceutical development, manufacturing, and packaging services — with specialisations in sterile multidoses, lyophilisation, and sachets/stick packs — to pharmaceutical and biotech clients.

What Meribel Pharma Solutions does

Meribel Pharma Solutions is a UK-headquartered, mid-size European pharmaceutical Contract Development and Manufacturing Organisation (CDMO) that was formed in 2024 through the merger of Synerlab Group and seven manufacturing sites formerly operated by Recipharm, and officially launched commercial operations in April 2025. The company operates an integrated network of 13 manufacturing facilities — six in France, two in Spain, and five in Sweden — with more than 2,000 full-time employees across five countries, and is backed by Blue Wolf Capital Partners, a US middle-market private equity firm focused on industrial and healthcare sectors.

The company offers end-to-end CDMO services spanning formulation development, analytical development, process development, commercial-scale manufacturing, packaging, regulatory affairs, technology transfer, and specials (unlicensed medicines). It manufactures across five principal dosage forms — oral solids, liquids, semi-solids, steriles, and sachets/stick packs — with particular domain specialisation in sterile multidoses (drawing on over three decades of legacy expertise), lyophilisation (including cryogenic and API lyophilisation), and sachets/stick packs. Multiple sites hold cGMP (EU), FDA, and PMDA (Japan) certifications, along with ISO 13485, 14001, and 45001 credentials at Swedish sites, enabling the company to serve pharmaceutical clients across major regulated markets.

Meribel operates a B2B contract-services revenue model, generating revenue through long-term commercial supply and development contracts with pharmaceutical companies — including generic drug manufacturers, innovative pharma, and biotechs — at negotiated per-project pricing. The go-to-market is enterprise sales-led, supported by a Chief Commercial Officer, dedicated commercial teams, and active presence at industry events such as CPHI Frankfurt (October 2025) and CDMO Live Rotterdam (May 2026, Gold Partner). The company has stated an ambition to double revenue within five years under Blue Wolf Capital's ownership.

Meribel Pharma Solutions firmographics

Firmographics
Name
Meribel Pharma Solutions
Legal name
BW CDMO Topco Uk Limited
Website
https://meribelpharma.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Meribel Pharma Solutions is a UK-headquartered mid-size European CDMO operating 13 manufacturing sites across France, Spain, and Sweden with 2,000+ staff, offering end-to-end pharmaceutical development, manufacturing, and packaging services — with specialisations in sterile multidoses, lyophilisation, and sachets/stick packs — to pharmaceutical and biotech clients.
Ownership category
akta.pro rank

Meribel Pharma Solutions industry classification

Industry
Product category
Pharmaceutical Contract Manufacturing (CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Contract pharmaceutical manufacturing
  • Lyophilisation services
  • Sterile manufacturing
  • Oral solid dose
  • Pharmaceutical development services

Where Meribel Pharma Solutions is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices13 records

Markets served

Meribel Pharma Solutions business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Contract Development and Manufacturing Services: As a CDMO, Meribel Pharma Solutions generates revenue through providing end-to-end pharmaceutical development and manufacturing services to pharmaceutical companies. Services include formulation development, analytical development, process development, manufacturing, packaging, regulatory affairs, and technology transfer. Revenue is generated through long-term contracts with pharmaceutical companies for product development and commercial manufacturing.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Meribel Pharma Solutions product offering

Product offering

Core offering

Meribel Pharma Solutions is a mid-size European Contract Development and Manufacturing Organisation (CDMO) providing end-to-end pharmaceutical services from concept through commercialisation. The company delivers formulation development, analytical development, process development, manufacturing, packaging, regulatory affairs, and technology transfer across 13 manufacturing sites in France, Spain, and Sweden. Core specialisations include lyophilisation (including API and cryogenic), sterile multidose manufacturing with terminal sterilisation, sachets and stick packs, oral solid dose production, semi-solids, and sterile non-injectable liquids for pharmaceutical company clients.

Product overview

Meribel Pharma Solutions is a mid-size, full-service Contract Development and Manufacturing Organisation (CDMO) offering an integrated network of pharmaceutical development and manufacturing services across Europe. The company's product portfolio includes three core service areas: Development Services (comprising Formulation Development, Analytical Development, and Process Development), Manufacturing Services for multiple dosage forms, and Regulatory Affairs. The company specialises in five key dosage forms: Oral Solids, Liquids, Semi-Solids, Steriles, and Sachets/Stick Packs. The service offering is built around particular specialisations in sterile multidoses, sterile and non-sterile lyophilised products, API lyophilisation, sachets and stick packs. Additional services include Packaging, Technology Transfer, Specials, and Quality assurance. The integrated network across 13 sites in France, Spain, and Sweden enables seamless support from concept through to commercialisation.

Differentiator

Problem solved

Functional benefit

Products and services

  • Lyophilisation Services Flexible and responsive lyophilisation (freeze-drying) services across the entire value chain, with particular specialisation in API lyophilisation and cryogenic/extreme cold processing capabilities. Sold to pharmaceutical companies requiring contract lyophilisation manufacturing.
  • Sterile Multidose Services Expert sterile multidose development and manufacturing services with over three decades of experience, including sterile and non-sterile lyophilised products, terminal sterilisation, and WFI (Water for Injection) production. Sold to pharmaceutical companies.
  • Development Services Comprehensive drug development services including formulation development, analytical development, and process development for pharmaceutical clients. Sold as an integrated development service to pharmaceutical companies.
  • Manufacturing Services Diverse manufacturing technologies and experienced team ensuring high-quality and efficient production of drug products across multiple dosage forms. Sold as contract manufacturing to pharmaceutical companies.
  • Packaging Services Pharmaceutical packaging solutions grounded in knowledge and insight, including large-scale sachet and stick pack packaging capacity. Sold as contract packaging services to pharmaceutical companies.
  • Regulatory Affairs Services Regulatory affairs services in the EU to help navigate the complexities of global pharmaceutical regulations for medicinal products. Sold to pharmaceutical companies requiring multi-jurisdictional regulatory support.
  • Technology Transfer Services Flexible approach to technology transfer that adapts to unique customer requirements and timelines, enabling seamless movement of products and processes between sites. Sold to pharmaceutical companies requiring tech transfer support.
  • Specials Services Solutions for complex pharmaceutical challenges where standard approaches may not apply. Sold to pharmaceutical companies requiring tailored manufacturing solutions for complex products.

Companies that use Meribel Pharma Solutions

Customer profile

Segments2 records

Ideal customer profiles1 record

Meribel Pharma Solutions technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Meribel Pharma Solutions partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Meribel Pharma Solutions competitors and assessment

Company assessment

Broad incumbents

  • Almac Group: UK/Northern Ireland-headquartered CDMO with comparable pharmaceutical development, manufacturing, and clinical services. Competes for similar European pharma contracts at greater scale and broader service breadth.
  • Lonza: Swiss-headquartered global CDMO leader across small molecules, biologics, and cell/gene therapy. Operates at much larger scale than Meribel but competes for the same European pharma outsourcing wallet, particularly for sterile and complex dosage forms.
  • Catalent: Global large-molecule and small-molecule CDMO with comparable service lines (oral solids, sterile, softgel, biologics). Competes with Meribel for mid-tier pharma contracts but at much greater scale and with broader dosage-form breadth.

Direct peers

  • Euroapi: European API and intermediates CDMO spun off from Sanofi in 2022. Comparable regulatory heritage, French-headquartered, and competing for the same European pharma outsourcing customers, particularly on API and complex synthesis.
  • Delpharm: French-headquartered CDMO specialising in sterile and non-sterile pharmaceutical manufacturing, particularly oral solids and injectables. Directly comparable European mid-size CDMO competing for the same generic and innovative-pharma customers as Meribel.
  • Fareva: France-based contract manufacturer with pharmaceutical (CDMO), cosmetic, and industrial operations. Comparable pharmaceutical manufacturing scale and European footprint, especially in France, competing in similar dosage forms.
  • Hovione: Portugal-headquartered CDMO specialising in API development and manufacturing, inhalation, and oral dosage forms. Comparable as a European specialist CDMO serving global pharma with similar regulatory certifications.
  • Recipharm: European CDMO focused on small-molecule drug product manufacturing across sterile, semi-solid, and oral solid dosage forms — directly comparable to Meribel across both service offering and target pharma customer base. Seven of Meribel's sites were carved out from Recipharm in 2024.
  • CordenPharma: European CDMO providing API manufacturing (peptides, lipids, carbohydrates) and drug product services across sterile and oral dosage forms. Comparable as a mid-to-large European CDMO platform serving global pharma customers.
  • Aenova: European mid-size CDMO with similar portfolio across solid, semi-solid, liquid, and sterile dosage forms. Comparable in scale and footprint, competing head-to-head for mid-size pharma contract manufacturing business.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Meribel Pharma Solutions social profiles

Digital presence

Meribel Pharma Solutions compliance and trust

Trust signal

Compliance10 records

Meribel Pharma Solutions financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Meribel Pharma Solutions leadership team

Management profile

Number of profiles

Profiles8 records

Meribel Pharma Solutions subsidiaries and ownership

Company hierarchy

Subsidiaries15 records

Meribel Pharma Solutions funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Meribel Pharma Solutions M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Meribel Pharma Solutions

What does Meribel Pharma Solutions do?

Meribel Pharma Solutions is a mid-size European Contract Development and Manufacturing Organisation (CDMO) providing end-to-end pharmaceutical services from concept through commercialisation. The company delivers formulation development, analytical development, process development, manufacturing, packaging, regulatory affairs, and technology transfer across 13 manufacturing sites in France, Spain, and Sweden. Core specialisations include lyophilisation (including API and cryogenic), sterile multidose manufacturing with terminal sterilisation, sachets and stick packs, oral solid dose production, semi-solids, and sterile non-injectable liquids for pharmaceutical company clients.

Is Meribel Pharma Solutions a public or private company?

Meribel Pharma Solutions is a private company. It is classified as private equity controlled and is currently operating.

When was Meribel Pharma Solutions founded?

Meribel Pharma Solutions was founded in 2024. It employs 501 to 1,000 people.

Where is Meribel Pharma Solutions based?

Meribel Pharma Solutions is headquartered in London, United Kingdom, in the Europe region.

How does Meribel Pharma Solutions make money?

One revenue line is on record: contract Development and Manufacturing Services.

Who are Meribel Pharma Solutions's main competitors?

Broad incumbents on record are Almac Group, Lonza and Catalent. Direct peers are Euroapi, Delpharm, Fareva, Hovione, Recipharm, CordenPharma and Aenova.

Does Meribel Pharma Solutions have an API?

No public API is recorded for Meribel Pharma Solutions.

What industry is Meribel Pharma Solutions in?

Meribel Pharma Solutions's product category is Pharmaceutical Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals